- CEO
- Jiande Chen
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- United States of America
- Business
- Redwoods Acquisition Corp. (RWODW) operates as warrants associated with a former blank check company whose common shares and warrants underwent a business combination with ANEW Medical, Inc., completed on June 21, 2024; the post-merger entity trades as ANEW Medical, Inc. under tickers WENA (common stock) and WENAW (warrants) on Nasdaq Global Market and Capital Market, respectively, while RWODW warrants represent legacy public warrants exercisable into the combined company's shares. As a special purpose acquisition company originally incorporated in 2021 and headquartered in New York, New York, Redwoods Acquisition Corp. historically pursued mergers, share exchanges, asset acquisitions, stock purchases, recapitalizations, or similar combinations targeting carbon neutral and energy storage industries outside China; its main activities centered on identifying and executing a de-SPAC transaction rather than direct products or services. In its latest major change, Redwoods closed the definitive merger with ANEW Medical on June 21, 2024, following shareholder approval on April 12, 2024, transforming into a biopharmaceutical technology firm advancing diagnostics and novel disease-modifying therapies for central nervous system and neurodegenerative disorders such as ALS, Alzheimer's, Parkinson's, and age-related conditions using gene therapy platforms; the deal provided approximately $54 million in cash proceeds (pre-redemptions) at a pro forma enterprise value of $94 million, with ANEW shareholders rolling 100% equity and eligible for earn-outs.